(firstQuint)Tolerability, Pharmacokinetics and Dopamine -hydroxylase (DH) Inhibition Profile of BIA 5-453.

 Single centre, randomised, double-blind, placebo-controlled study of single ascending doses in 10 sequential groups of 8 healthy young male volunteers.

 Within each group (n=8), 6 volunteers were randomised to receive BIA 5-453 and the remaining 2 volunteers were randomised to receive placebo.

 A volunteer participated only in a single period.

.

 Tolerability, Pharmacokinetics and Dopamine -hydroxylase (DH) Inhibition Profile of BIA 5-453@highlight

The purpose of this study is to assess the safety and tolerability of BIA 5-453 after single oral doses